Drug Profile

Factor VIII gene therapy - Targeted Genetics

Latest Information Update: 24 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of North Carolina
Class Blood coagulation factors; Coagulants
Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Haemophilia A

Most Recent Events

09 May 2019 C3J Therapeutics has merged with AmpliPhi Biosciences Corporation to form Armata Pharmaceuticals
24 Nov 2003 Suspended - Preclinical for Haemophilia A in USA (Injection)
26 Jan 2000 An animal study has been added to the Haematological disorders pharmacodynamics section

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com